New ointment aims to restore skin color in vitiligo

NCT ID NCT07682506

Not yet recruiting Disease control Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This Phase 3 trial tests whether an ointment called MH004 can help restore skin color in people with non-segmental vitiligo. The study includes adolescents and adults aged 12 to 75 with facial vitiligo. Participants apply the ointment twice daily for 24 weeks, and researchers measure improvement in skin repigmentation compared to a placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MH004 ointment
What this could lead to: If successful, this could offer a new topical treatment to restore skin color in people with vitiligo.
What could go wrong: This is a Phase 3 trial, so results are not yet confirmed. The ointment may not work for everyone, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VITILIGO are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

vitiligo

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

VITILIGO

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Peking University People's Hospital

Beijing, Beijing Municipality, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.